Why Faster AI Submissions Mean Slower Approvals: IQVIA on Regulatory Velocity

MedTech and Pharma companies are using AI to speed up regulatory submissions, but many are finding that faster output is actually leading to more rejections. This episode unpacks a 2026 white paper from IQVIA detailing why speed-first AI fails by treating regulations like a checklist, missing crucial cross-functional inconsistencies. Listeners will learn why shifting from pure speed to patient-centric velocity—and embedding AI directly into regulatory workflows—is the only way to build defensible submissions that regulators can trust.

Key points

• AI optimized solely for throughput validates completeness rather than correctness, accelerating mistakes and hallucinations.
• Speed-first AI systems miss cross-functional inconsistencies between clinical evidence, technical data, quality, and labeling claims.
• Global regulators now have access to their own AI tools, allowing them to spot disjointed, speed-driven submissions instantly.
• IQVIA argues for a shift to velocity—speed combined with intentional, patient-centric direction grounded in clinical evidence.
• AI should be embedded directly into Regulatory Information Management workflows rather than layered on top, catching potential objections before submission.
• Accountability remains with human regulatory professionals, who must ensure the submission tells a clear, defensible story about patient safety.

Source: Speed Can Mislead: Why Velocity Matters Most in Global Regulatory Affairs - IQVIA, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/why-faster-ai-submissions-mean-slower-approvals-iqvia-on-regulatory-ve-0bafdc